THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 93 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,035,299 | -20.2% | 115,418 | 0.0% | 0.00% | 0.0% |
Q4 2023 | $1,297,298 | +77.5% | 115,418 | +36.3% | 0.00% | 0.0% |
Q3 2023 | $730,831 | -19.2% | 84,685 | -3.1% | 0.00% | 0.0% |
Q2 2023 | $904,465 | -47.9% | 87,388 | -45.4% | 0.00% | -50.0% |
Q1 2023 | $1,735,382 | +54.3% | 159,943 | +59.6% | 0.00% | +100.0% |
Q4 2022 | $1,124,525 | +54.7% | 100,225 | +39.9% | 0.00% | 0.0% |
Q3 2022 | $727,000 | +12.5% | 71,620 | +0.5% | 0.00% | 0.0% |
Q2 2022 | $646,000 | +3.5% | 71,238 | +9.0% | 0.00% | 0.0% |
Q1 2022 | $624,000 | -14.8% | 65,348 | -1.4% | 0.00% | – |
Q4 2021 | $732,000 | +41.9% | 66,261 | -4.9% | 0.00% | – |
Q3 2021 | $516,000 | -43.3% | 69,653 | +11.1% | 0.00% | – |
Q2 2021 | $910,000 | -8.6% | 62,722 | +28.4% | 0.00% | -100.0% |
Q1 2021 | $996,000 | -10.4% | 48,834 | -21.9% | 0.00% | 0.0% |
Q4 2020 | $1,111,000 | +67.3% | 62,519 | +39.0% | 0.00% | – |
Q3 2020 | $664,000 | -72.0% | 44,985 | -60.2% | 0.00% | -100.0% |
Q2 2020 | $2,373,000 | -27.0% | 113,052 | -19.7% | 0.00% | -33.3% |
Q1 2020 | $3,252,000 | -15.2% | 140,725 | -5.0% | 0.00% | 0.0% |
Q4 2019 | $3,836,000 | +126.0% | 148,141 | +70.0% | 0.00% | +200.0% |
Q3 2019 | $1,697,000 | +375.4% | 87,165 | +298.4% | 0.00% | – |
Q2 2019 | $357,000 | -63.6% | 21,877 | -49.5% | 0.00% | -100.0% |
Q1 2019 | $981,000 | -1.6% | 43,279 | +11.0% | 0.00% | 0.0% |
Q4 2018 | $997,000 | -9.1% | 38,981 | +16.1% | 0.00% | 0.0% |
Q3 2018 | $1,097,000 | -1.6% | 33,583 | -31.7% | 0.00% | 0.0% |
Q2 2018 | $1,115,000 | -16.2% | 49,184 | -10.3% | 0.00% | 0.0% |
Q1 2018 | $1,330,000 | +3.5% | 54,849 | +19.0% | 0.00% | 0.0% |
Q4 2017 | $1,285,000 | -36.6% | 46,092 | -22.2% | 0.00% | -50.0% |
Q3 2017 | $2,027,000 | +48.6% | 59,211 | +72.9% | 0.00% | +100.0% |
Q2 2017 | $1,364,000 | -5.6% | 34,237 | -12.8% | 0.00% | 0.0% |
Q1 2017 | $1,445,000 | -3.9% | 39,246 | -16.8% | 0.00% | 0.0% |
Q4 2016 | $1,503,000 | -64.4% | 47,188 | -59.5% | 0.00% | -75.0% |
Q3 2016 | $4,227,000 | +51.5% | 116,630 | -5.2% | 0.00% | +33.3% |
Q2 2016 | $2,791,000 | +42.8% | 123,022 | +18.3% | 0.00% | +50.0% |
Q1 2016 | $1,955,000 | +12.8% | 103,979 | -1.6% | 0.00% | 0.0% |
Q4 2015 | $1,733,000 | +55.0% | 105,715 | +3.9% | 0.00% | +100.0% |
Q3 2015 | $1,118,000 | -34.1% | 101,703 | -22.0% | 0.00% | -50.0% |
Q2 2015 | $1,697,000 | -15.7% | 130,352 | +12.4% | 0.00% | 0.0% |
Q1 2015 | $2,012,000 | +19.4% | 116,003 | +2.7% | 0.00% | +100.0% |
Q4 2014 | $1,685,000 | -21.4% | 112,964 | +21.3% | 0.00% | -50.0% |
Q3 2014 | $2,145,000 | +16.8% | 93,152 | +61.7% | 0.00% | 0.0% |
Q2 2014 | $1,836,000 | – | 57,593 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |